Enzyme – Talk Bio

Actionable Insights Powered by AI

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

2 weeks ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

1 month ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

AbbVie’s Rinvoq cleared for giant cell arteritis in US

1 month ago talkbio0Tagged Approved, Giant Cell Arteritis, Inhibitor, Janus kinase, Rinvoq, Steroids, United States Food and Drug Administration, upadacitinib

Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids

AIRNA nets $155M series B to launch clinical test of RNA editing tech

2 months ago talkbio0Tagged AIR-001, Airna, RNA, RNA Editing

RNA Editing, Airna, AIR-001, RNA

FDA clears Exelixis’ TKI for neuroendocrine tumours

2 months ago talkbio0Tagged Approved, Cabometyx, cabozantinib, Exelixis, Neoplasms, Neurosecretory Systems, Protein Tyrosine Kinase, United States Food and Drug Administration

CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso

2 months ago talkbio0Tagged Combined, Continuance of life, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso

Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso

Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

3 months ago talkbio0Tagged Creatine Kinase, Del-zota, DMD, Dystrophin, exon, Muscular Dystrophy, Duchenne, production, RNA, safety profile, skipping

Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile

Incyte’s oral HS drug hits study goals, but fails to excite investors

3 months ago talkbio0Tagged Effectiveness, Hidradenitis, Inhibitor, investor, Janus kinase 1, Phase 3 trials, povorcitinib, regulatory, suppurativa

povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission

AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes

3 months ago talkbio0Tagged Alteogen, AstraZeneca, Enzymes, Halozyme, hyaluronidase, Legal patent, licensing agreement, Merck, Subcutaneous Cancer

AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme